PT-141 regulatory status in 2026: what is actually approved
One molecule, two regulatory identities — branded and compounded.
TL;DR
- PT-141 (bremelanotide) is FDA-approved as Vyleesi for one specific indication in premenopausal women.
- Compounded PT-141 is dispensed by state-licensed 503A pharmacies and is not itself FDA-approved.
- PT-141 is not on the FDA Category 2 restricted list, which means access through a licensed prescriber is clearer than for several other peptides in 2026.
How it works
Think of a drug's regulatory identity like a building permit. The molecule bremelanotide has one approved permit — Vyleesi, for premenopausal women with HSDD (hypoactive sexual desire disorder — persistent low desire that causes distress). That permit was issued by the FDA in 2019 (Vyleesi label, FDA, 2019). A compounding pharmacy that prepares bremelanotide as a custom dose has no such permit. It works under a different rule book — the 503A pharmacy framework — with state board of pharmacy oversight (FDA compounding Q&A, 2024). Different builder. No permit for the product. Different oversight.
What it is
PT-141 is a melanocortin receptor agonist (in plain English: a molecule that switches on a specific brain receptor involved in sexual desire). Its branded form, Vyleesi, is FDA-approved for one defined condition. Compounded PT-141 is a different product that a 503A pharmacy prepares. FDA has not approved it. That single sentence is what most people are searching for when they look up the regulatory status.
Who asks about it
People come to this question after seeing PT-141 mentioned on a podcast, in a clinic ad, or in a friend's protocol. They want a clear answer: is this legal, is the FDA on board, and what does a physician actually prescribe. Many have been told contradictory things online. The honest answer is short and worth giving plainly.
What the research says
The Vyleesi approval was based on the RECONNECT trial program, which studied bremelanotide in premenopausal women with acquired HSDD. The active ingredient has additional published research in male sexual dysfunction and obesity-linked melanocortin biology, but those uses are not FDA-approved indications. Compounded PT-141 access is supported under FDA compounding policy when there is a documented patient-specific need a physician identifies — the standard 503A framework. Studied for its effects on sexual desire and arousal. Off-label prescribing by a licensed prescriber is legal in many states under standard medical practice rules.
What to know before considering it
PT-141 access requires a licensed physician. Common reported side effects include nausea (about 4 in 10 people in the Vyleesi trials), headache, and flushing — usually peaking 1 to 2 hours after the injection. Generally well-tolerated in physician-supervised protocols. Contraindications include uncontrolled high blood pressure and known cardiovascular disease. Individual response varies.
The Halftime POV
PT-141 has one of the cleanest regulatory pictures in our category: an FDA-approved version for one indication, a compounded version for physician-directed off-label use, and no Category 2 restriction. We give people the picture, name the indication, and point them to a licensed physician. We do not oversell the molecule. We tell them what is actually approved and what is not.
Related reading:
- PT-141 (bremelanotide): how melanocortin signaling affects desire
- Bremelanotide is FDA-approved for women: what Vyleesi actually treats
- Category 1 vs Category 2 peptides
FAQ
Q: Is PT-141 FDA-approved? A: The active ingredient bremelanotide is FDA-approved as Vyleesi for one specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 preparations are not themselves FDA-approved.
Q: Is compounded PT-141 legal? A: Compounded PT-141 is dispensed by state-licensed 503A pharmacies with a valid prescription from a licensed physician. The compounded preparation is not FDA-approved. Access rules vary by state.
Q: Can men use PT-141? A: Vyleesi is FDA-approved for premenopausal women only. Off-label prescribing by a licensed prescriber is legal in many states. Off-label use is at physician discretion based on the published literature.
Q: Is PT-141 a Category 2 peptide? A: No. PT-141 is not on the FDA Category 2 list. It can be compounded by 503A pharmacies. This is one of the few intimacy-related peptides with a clear access path in 2026.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary.
Get started
We share what we learn along the way — the research, the regulations, the real-world trade-offs. Get started with Halftime Health.
Sources
This article discusses compounds whose FDA compounding status has been under review (see our FDA categorization explainer). This article is provided for educational purposes only and does not constitute medical advice or an offer to sell.
Frequently asked questions
Is PT-141 FDA-approved?
The active ingredient bremelanotide is FDA-approved as Vyleesi for one specific indication: acquired, generalized hypoactive sexual desire disorder in premenopausal women. Compounded PT-141 preparations are not themselves FDA-approved.
Is compounded PT-141 legal?
Compounded PT-141 is dispensed by state-licensed 503A pharmacies with a valid prescription from a licensed physician. The compounded preparation is not FDA-approved. Access rules vary by state.
Can men use PT-141?
Vyleesi is FDA-approved for premenopausal women only. Off-label prescribing by a licensed prescriber is legal in many states. Off-label use is at physician discretion based on the published literature.
Is PT-141 a Category 2 peptide?
No. PT-141 is not on the FDA Category 2 list. It can be compounded by 503A pharmacies. This is one of the few intimacy-related peptides with a clear access path in 2026.
Keep reading
Every protocol is reviewed by a licensed physician and filled by a licensed 503A compounding pharmacy.
Membership from $39/mo, or $390 for the year, including your onboarding panel. Each protocol is its own monthly subscription.